Millions of total joint replacements are performed annually worldwide, and the number is increasing every year. The overall proportion of patients achieving a successful outcome is about 80-90% in a 10-20-years time horizon postoperatively, periprosthetic osteolysis (PPOL) and aseptic loosening (AL) being the most frequent reasons for knee and hip implant failure and reoperations. The chemokine system (chemokine receptors and chemokines) is crucially involved in the inflammatory and osteolytic processes leading to PPOL/AL. Thus, the modulation of the interactions within the chemokine system may influence the extent of PPOL. Indeed, recent studies in murine models reported that (i) blocking the CCR2-CCL2 or CXCR2-CXCL2 axis or (ii) activation of the CXCR4-CXCL12 axis attenuate the osteolysis of artificial joints. Importantly, chemokines, inhibitory mutant chemokines, antagonists of chemokine receptors, or neutralizing antibodies to the chemokine system attached to or incorporated into the implant surface may influence the tissue responses and mitigate PPOL, thus increasing prosthesis longevity. This review summarizes the current state of the art of the knowledge of the chemokine system in human PPOL/AL. Furthermore, the potential for attenuating cell trafficking to the bone-implant interface and influencing tissue responses through modulation of the chemokine system is delineated. Additionally, the prospects of using immunoregenerative biomaterials (including chemokines) for the prevention of failed implants are discussed. Finally, this review highlights the need for a more sophisticated understanding of implant debris-induced changes in the chemokine system to mitigate this response effectively.

Faculty of Medicine and Dentistry Department of Immunology Palacky University Olomouc Olomouc Czechia

Faculty of Medicine and Dentistry Department of Orthopaedics Palacky University Olomouc University Hospital Olomouc Olomouc Czechia

Zobrazit více v PubMed

Cavalli L, Brandi ML. Periprosthetic bone loss: diagnostic and therapeutic approaches. F1000Res (2014) 2:266.10.12688/f1000research.2-266.v2 PubMed DOI PMC

Gallo J, Kamínek P, Tichá V, Riháková P, Ditmar R. Particle disease. A comprehensive theory of periprosthetic osteolysis: a review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2002) 146:21–8.10.5507/bp.2002.004 PubMed DOI

Goodman SB, Ma T. Cellular chemotaxis induced by wear particles from joint replacements. Biomaterials (2010) 31:5045–50.10.1016/j.biomaterials.2010.03.046 PubMed DOI PMC

Gu Q, Shi Q, Yang H. The role of TLR and chemokine in wear particle-induced aseptic loosening. J Biomed Biotechnol (2012) 2012:596870.10.1155/2012/596870 PubMed DOI PMC

Purdue PE, Koulouvaris P, Potter HG, Nestor B, Sculco JTP. The cellular and molecular biology of periprosthetic osteolysis. Clin Orthop Relat Res (2007) 454:251–61.10.1097/01.blo.0000238813.95035.1b PubMed DOI

Gallo J, Goodman SB, Konttinen YT, Raska M. Particle disease: biologic mechanisms of periprosthetic osteolysis in total hip arthroplasty. Innate Immun (2013) 19:213–24.10.1177/1753425912451779 PubMed DOI PMC

Gallo J, Goodman SB, Konttinen YT, Wimmer MA, Holinka M. Osteolysis around total knee arthroplasty: a review of pathogenetic mechanisms. Acta Biomater (2013) 9:8046–58.10.1016/j.actbio.2013.05.005 PubMed DOI PMC

Koizumi K, Saitoh Y, Minami T, Takeno N, Tsuneyama K, Miyahara T, et al. Role of CX3CL1/fractalkine in osteoclast differentiation and bone resorption. J Immunol (2009) 183:7825–31.10.4049/jimmunol.0803627 PubMed DOI

Mohan K, Issekutz TB. Blockade of chemokine receptor CXCR3 inhibits T cell recruitment to inflamed joints and decreases the severity of adjuvant arthritis. J Immunol (2007) 179:8463–9.10.4049/jimmunol.179.12.8463 PubMed DOI

Fu R, Liu H, Zhao S, Wang Y, Li L, Gao S, et al. Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease. Cancer Cell Int (2014) 14:132.10.1186/s12935-014-0132-6 PubMed DOI PMC

Diamond P, Labrinidis A, Martin SK, Farrugia AN, Gronthos S, To LB, et al. Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss. J Bone Miner Res (2009) 24:1150–61.10.1359/jbmr.090210 PubMed DOI

Gibon E, Ma T, Ren PG, Fritton K, Biswal S, Yao Z, et al. Selective inhibition of the MCP-1-CCR2 ligand-receptor axis decreases systemic trafficking of macrophages in the presence of UHMWPE particles. J Orthop Res (2012) 30:547–53.10.1002/jor.21548 PubMed DOI PMC

Wang C, Liu Y, Wang Y, Li H, Zhang RX, He MS, et al. Adenovirus-mediated siRNA targeting CXCR2 attenuates titanium particle-induced osteolysis by suppressing osteoclast formation. Med Sci Monit (2016) 22:727–35.10.12659/MSM.897243 PubMed DOI PMC

Thevenot PT, Nair AM, Shen J, Lotfi P, Ko CY, Tang L. The effect of incorporation of SDF-1alpha into PLGA scaffolds on stem cell recruitment and the inflammatory response. Biomaterials (2010) 31:3997–4008.10.1016/j.biomaterials.2010.01.144 PubMed DOI PMC

Kim YH, Tabata Y. Recruitment of mesenchymal stem cells and macrophages by dual release of stromal cell-derived factor-1 and a macrophage recruitment agent enhances wound closure. J Biomed Mater Res A (2016) 104:942–56.10.1002/jbm.a.35635 PubMed DOI

Nabeshima A, Pajarinen J, Lin TH, Jiang X, Gibon E, Córdova LA, et al. Mutant CCL2 protein coating mitigates wear particle-induced bone loss in a murine continuous polyethylene infusion model. Biomaterials (2017) 117:1–9.10.1016/j.biomaterials.2016.11.039 PubMed DOI PMC

Lodowski DT, Palczewski K. Chemokine receptors and other G protein-coupled receptors. Curr Opin HIV AIDS (2009) 4:88–95.10.1097/COH.0b013e3283223d8d PubMed DOI PMC

Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity (2012) 36:705–16.10.1016/j.immuni.2012.05.008 PubMed DOI PMC

Maravillas-Montero JL, Burkhardt AM, Hevezi PA, Carnevale CD, Smit MJ, Zlotnik A. Cutting edge: GPR35/CXCR8 is the receptor of the mucosal chemokine CXCL17. J Immunol (2015) 194:29–33.10.4049/jimmunol.1401704 PubMed DOI PMC

Bachelerie F, Graham GJ, Locati M, Mantovani A, Murphy PM, Nibbs R, et al. New nomenclature for atypical chemokine receptors. Nat Immunol (2014) 15:207–8.10.1038/ni.2812 PubMed DOI

Bonecchi R, Graham GJ. Atypical chemokine receptors and their roles in the resolution of the inflammatory response. Front Immunol (2016) 7:224.10.3389/fimmu.2016.00224 PubMed DOI PMC

Stone MJ, Hayward JA, Huang C, Huma ZE, Sanchez J. Mechanisms of regulation of the chemokine-receptor network. Int J Mol Sci (2017) 18:342.10.3390/ijms18020342 PubMed DOI PMC

Gale LM, McColl SR. Chemokines: extracellular messengers for all occasions? Bioessays (1999) 21:17–28.10.1002/(SICI)1521-1878(199901)21:1<17::AID-BIES3>3.0.CO;2-4 PubMed DOI

Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol (2000) 18:217–42.10.1146/annurev.immunol.18.1.217 PubMed DOI

Moser B. Chemokines: role in immune cell traffic. Eur Cytokine Netw (2003) 14:204–10. PubMed

Le Y, Zhou Y, Iribarren P, Wang J. Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Mol Immunol (2004) 1:95–104. PubMed

Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol (2014) 32:659–702.10.1146/annurev-immunol-032713-120145 PubMed DOI

Tomankova T, Kriegova E, Liu M. Chemokine receptors and their therapeutic opportunities in diseased lung: far beyond leukocyte trafficking. Am J Physiol Lung Cell Mol Physiol (2015) 308:L603–18.10.1152/ajplung.00203.2014 PubMed DOI

Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol (2017).10.1038/nri.2017.49 PubMed DOI PMC

Viola A, Luster AD. Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol (2008) 48:171–97.10.1146/annurev.pharmtox.48.121806.154841 PubMed DOI

Grayson MH, Holtzman MJ. Chemokine signaling regulates apoptosis as well as immune cell traffic in host defense. Cell Cycle (2006) 5:380–3.10.4161/cc.5.4.2427 PubMed DOI

Dimberg A. Chemokines in angiogenesis. Curr Top Microbiol Immunol (2010) 341:59–80.10.1007/82_2010_21 PubMed DOI

Lisignoli G, Toneguzzi S, Piacentini A, Cristino S, Grassi F, Cavallo C, et al. CXCLl2(SDF-l) and CXCLl3 (BCA-1) chemokines significantly induce proliferation and collagen type I expression in osteoblasts from osteoarthritis patients. J Cell Physiol (2006) 206:78–85.10.1002/jcp.20435 PubMed DOI

Koulouvaris P, Ly K, Ivashkiv LB, Bostrom MP, Nestor BJ, Sculco TP, et al. Expression profiling reveals alternative macrophage activation and impaired osteogenesis in periprosthetic osteolysis. J Orthop Res (2008) 26:106–16.10.1002/jor.20486 PubMed DOI

Tomankova T, Kriegova E, Fillerova R, Luzna P, Ehrmann J, Gallo J. Comparison of periprosthetic tissues in knee and hip joints: differential expression of CCL3 and DC-STAMP in total knee and hip arthroplasty and similar cytokine profiles in primary knee and hip osteoarthritis. Osteoarthritis Cartilage (2014) 22:1851–60.10.1016/j.joca.2014.08.004 PubMed DOI

Dasa V, Kramer JM, Gaffen SL, Kirkwood KL, Mihalko WM. Is monocyte chemotactic protein 1 elevated in aseptic loosening of TKA? A pilot study. Clin Orthop Relat Res (2012) 470:1879–84.10.1007/s11999-011-2191-5 PubMed DOI PMC

Shanbhag AS, Kaufman AM, Hayata K, Rubash HE. Assessing osteolysis with use of high-throughput protein chips. J Bone Joint Surg Am (2007) 89:1081–9.10.2106/JBJS.F.00330 PubMed DOI

Jämsen E, Kouri VP, Ainola M, Goodman SB, Nordström DC, Eklund KK, et al. Correlations between macrophage polarizing cytokines, inflammatory mediators, osteoclast activity, and toll-like receptors in tissues around aseptically loosened hip implants. J Biomed Mater Res A (2017) 105:454–63.10.1002/jbm.a.35913 PubMed DOI

Kolatat K, Perino G, Wilner G, Kaplowitz E, Ricciardi BF, Boettner F, et al. Adverse local tissue reaction (ALTR) associated with corrosion products in metal-on-metal and dual modular neck total hip replacements is associated with upregulation of interferon gamma-mediated chemokine signalling. J Orthop Res (2015) 33:1487–97.10.1002/jor.22916 PubMed DOI

Szekanecz Z, Vegvari A, Szabo Z, Koch AE. Chemokines and chemokine receptors in arthritis. Front Biosci (Schol Ed) (2010) 2:153–67.10.2741/s53 PubMed DOI PMC

Hameed A, Brady JJ, Dowling P, Clynes M, O’Gorman P. Bone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis (2014) 7:33–42.10.4137/CGM.S16817 PubMed DOI PMC

Goodman SB, Gibon E, Pajarinen J, Lin TH, Keeney M, Ren PG, et al. Novel biological strategies for treatment of wear particle-induced periprosthetic osteolysis of orthopaedic implants for joint replacement. J R Soc Interface (2014) 11:20130962.10.1098/rsif.2013.0962 PubMed DOI PMC

Hallab NJ, Jacobs JJ. Chemokines associated with pathologic responses to orthopedic implant debris. Front Endocrinol (2017) 8:5.10.3389/fendo.2017.00005 PubMed DOI PMC

Muñoz LM, Lucas P, Holgado BL, Barroso R, Vega B, Rodríguez-Frade JM, et al. Receptor oligomerization: a pivotal mechanism for regulating chemokine function. Pharmacol Ther (2011) 131:351–8.10.1016/j.pharmthera.2011.05.002 PubMed DOI

Stephens B, Handel TM. Chemokine receptor oligomerization and allostery. Prog Mol Biol Transl Sci (2013) 115:375–420.10.1016/B978-0-12-394587-7.00009-9 PubMed DOI PMC

Yu X, Huang Y, Collin-Osdoby P, Osdoby P. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J Bone Miner Res (2004) 19:2065–77.10.1359/jbmr.040910 PubMed DOI

Wright LM, Maloney W, Yu X, Kindle L, Collin-Osdoby P, Osdoby P. Stromal cell-derived factor-1 binding to its chemokine receptor CXCR4 on precursor cells promotes the chemotactic recruitment, development and survival of human osteoclasts. Bone (2005) 36:840–53.10.1016/j.bone.2005.01.021 PubMed DOI

Kaufman AM, Alabre CI, Rubash HE, Shanbhag AS. Human macrophage response to UHMWPE, TiAlV, CoCr, and alumina particles: analysis of multiple cytokines using protein arrays. J Biomed Mater Res A (2008) 84:464–74.10.1002/jbm.a.31467 PubMed DOI

Green TR, Fisher J, Stone M, Wroblewski BM, Ingham E. Polyethylene particles of a ‘ritical size’ are necessary for the induction of cytokines by macrophages in vitro. Biomaterials (1998) 19:2297–302.10.1016/S0142-9612(98)00140-9 PubMed DOI

Boynton EL, Waddell J, Meek E, Labow RS, Edwards V, Santerre JP. The effect of polyethylene particle chemistry on human monocyte-macrophage function in vitro. J Biomed Mater Res (2000) 52:239–45.10.1002/1097-4636(200011)52:2<239::AID-JBM1>3.0.CO;2-R PubMed DOI

Illgen RL, Forsythe TM, Pike JW, Laurent MP, Blanchard CR. Highly crosslinked vs conventional polyethylene particles – an in vitro comparison of biologic activities. J Arthroplasty (2008) 23:721–31.10.1016/j.arth.2007.05.043 PubMed DOI

Gallo J, Slouf M, Goodman SB. The relationship of polyethylene wear to particle size, distribution, and number: a possible factor explaining the risk of osteolysis after hip arthroplasty. J Biomed Mater Res B Appl Biomater (2010) 94:171–7.10.1002/jbm.b.31638 PubMed DOI

Yaszay B, Trindade MC, Lind M, Goodman SB, Smith RL. Fibroblast expression of C-C chemokines in response to orthopaedic biomaterial particle challenge in vitro. J Orthop Res (2001) 19:970–6.10.1016/S0736-0266(01)00003-1 PubMed DOI

Koreny T, Tunyogi-Csapó M, Gál I, Vermes C, Jacobs JJ, Glant TT. The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis. Arthritis Rheum (2006) 54:3221–32.10.1002/art.22134 PubMed DOI

García-Vicuña R, Gómez-Gaviro MV, Domínguez-Luis MJ, Pec MK, González-Alvaro I, Alvaro-Gracia JM, et al. CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum (2004) 50:3866–77.10.1002/art.20615 PubMed DOI

Laragione T, Brenner M, Sherry B, Gulko PS. CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis. Arthritis Rheum (2011) 63:3274–83.10.1002/art.30573 PubMed DOI PMC

Liu X, Zhang H, Chang X, Shen J, Zheng W, Xu Y, et al. Upregulated expression of CCR3 in rheumatoid arthritis and CCR3-dependent activation of fibroblast-like synoviocytes. Cell Biol Toxicol (2017) 33:15–26.10.1007/s10565-016-9356-7 PubMed DOI

Brühl H, Mack M, Niedermeier M, Lochbaum D, Schölmerich J, Straub RH. Functional expression of the chemokine receptor CCR7 on fibroblast-like synoviocytes. Rheumatology (Oxford) (2008) 47:1771–4.10.1093/rheumatology/ken383 PubMed DOI

Nilsson A, Norgård M, Andersson G, Fahlgren A. Fluid pressure induces osteoclast differentiation comparably to titanium particles but through a molecular pathway only partly involving TNFα. J Cell Biochem (2012) 113:1224–34.10.1002/jcb.23456 PubMed DOI

Pajarinen J, Kouri VP, Jamsen E, Li TF, Mandelin J, Konttinen YT. The response of macrophages to titanium particles is determined by macrophage polarization. Acta Biomater (2013) 9:9229–40.10.1016/j.actbio.2013.06.027 PubMed DOI

Pathak JL, Bakker AD, Verschueren P, Lems WF, Luyten FP, Klein-Nulend J, et al. CXCL8 and CCL20 enhance osteoclastogenesis via modulation of cytokine production by human primary osteoblasts. PLoS One (2015) 10:e0131041.10.1371/journal.pone.0131041 PubMed DOI PMC

Cadosch D, Gautschi OP, Chan E, Simmen HP, Filgueira L. Titanium induced production of chemokines CCL17/TARC and CCL22/MDC in human osteoclasts and osteoblasts. J Biomed Mater Res A (2010) 92:475–83.10.1002/jbm.a.32390 PubMed DOI

Lisignoli G, Toneguzzi S, Piacentini A, Cattini L, Lenti A, Tschon M, et al. Human osteoblasts express functional CXC chemokine receptors 3 and 5: activation by their ligands, CXCL10 and CXCL13, significantly induces alkaline phosphatase and beta-N-acetylhexosaminidase release. J Cell Physiol (2003) 194:71–9.10.1002/jcp.10188 PubMed DOI

Shahnazari M, Chu V, Wronski TJ, Nissenson RA, Halloran BP. CXCL12/CXCR4 signaling in the osteoblast regulates the mesenchymal stem cell and osteoclast lineage populations. FASEB J (2013) 27:3505–13.10.1096/fj.12-225763 PubMed DOI

Drynda A, Ren Q, Buchhorn GH, Lohmann CH. The induction of CXCR4 expression in human osteoblast-like cells (MG63) by CoCr particles is regulated by the PLC-DAG-PKC pathway. J Biomed Mater Res B Appl Biomater (2016).10.1002/jbm.b.33770 PubMed DOI

Huang Z, Ma T, Ren PG, Smith RL, Goodman SB. Effects of orthopedic polymer particles on chemotaxis of macrophages and mesenchymal stem cells. J Biomed Mater Res A (2010) 94:1264–9.10.1002/jbm.a.32803 PubMed DOI PMC

Gibon E, Yao Z, Rao AJ, Zwingenberger S, Batke B, Valladares R, et al. Effect of a CCR1 receptor antagonist on systemic trafficking of MSCs and polyethylene particle-associated bone loss. Biomaterials (2012) 33:3632–8.10.1016/j.biomaterials.2012.02.003 PubMed DOI PMC

Haleem-Smith H, Argintar E, Bush C, Hampton D, Postma WF, Chen FH, et al. Biological responses of human mesenchymal stem cells to titanium wear debris particles. J Orthop Res (2012) 30:853–63.10.1002/jor.22002 PubMed DOI PMC

Kim MS, Magno CL, Day CJ, Morrison NA. Induction of chemokines and chemokine receptors CCR2b and CCR4 in authentic human osteoclasts differentiated with RANKL and osteoclast like cells differentiated by MCP-1 and RANTES. J Cell Biochem (2006) 97:512–8.10.1002/jcb.20649 PubMed DOI

Khan UA, Hashimi SM, Khan S, Quan J, Bakr MM, Forwood MR, et al. Differential expression of chemokines, chemokine receptors and proteinases by foreign body giant cells (FBGCs) and osteoclasts. J Cell Biochem (2014) 115:1290–8.10.1002/jcb.24781 PubMed DOI

Kim MS, Day CJ, Selinger CI, Magno CL, Stephens SR, Morrison NA. MCP-1-induced human osteoclast-like cells are tartrate-resistant acid phosphatase, NFATc1, and calcitonin receptor-positive but require receptor activator of NFkappaB ligand for bone resorption. J Biol Chem (2006) 281:1274–85.10.1074/jbc.M510156200 PubMed DOI

Grassi F, Piacentini A, Cristino S, Toneguzzi S, Cavallo C, Facchini A, et al. Human osteoclasts express different CXC chemokines depending on cell culture substrate: molecular and immunocytochemical evidence of high levels of CXCL10 and CXCL12. Histochem Cell Biol (2003) 120:391–400.10.1007/s00418-003-0587-3 PubMed DOI

Wysolmerski JJ. Osteocytic osteolysis: time for a second look? Bonekey Rep (2012) 1:229.10.1038/bonekey.2012.229 PubMed DOI PMC

Atkins GJ, Welldon KJ, Holding CA, Haynes DR, Howie DW, Findlay DM. The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles. Biomaterials (2009) 30:3672–81.10.1016/j.biomaterials.2009.03.035 PubMed DOI

Ormsby RT, Cantley M, Kogawa M, Solomon LB, Haynes DR, Findlay DM, et al. Evidence that osteocyte perilacunar remodelling contributes to polyethylene wear particle induced osteolysis. Acta Biomater (2016) 33:242–51.10.1016/j.actbio.2016.01.016 PubMed DOI

Jiang X, Sato T, Yao Z, Keeney M, Pajarinen J, Lin TH, et al. Local delivery of mutant CCL2 protein-reduced orthopaedic implant wear particle-induced osteolysis and inflammation in vivo. J Orthop Res (2016) 34:58–64.10.1002/jor.22977 PubMed DOI PMC

Hirbe AC, Rubin J, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, et al. Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone. Proc Natl Acad Sci U S A (2007) 104:14062–7.10.1073/pnas.0705203104 PubMed DOI PMC

Bostrom M, O’Keefe R, Implant Wear Symposium 2007 Biologic Work Group What experimental approaches (eg, in vivo, in vitro, tissue retrieval) are effective in investigating the biologic effects of particles? J Am Acad Orthop Surg (2008) 16:S63–7.10.5435/00124635-200800001-00013 PubMed DOI PMC

Langlois J, Hamadouche M. New animal models of wear-particle osteolysis. Int Orthop (2011) 35:245–51.10.1007/s00264-010-1143-0 PubMed DOI PMC

Alexis JD, Pyo RT, Chereshnev I, Katz J, Rollins BJ, Charo IF, et al. Inhibition of MCP-1/CCR2 signaling does not inhibit intimal proliferation in a mouse aortic transplant model. J Vasc Res (2008) 45:538–46.10.1159/000129688 PubMed DOI

Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med (2006) 354:610–21.10.1056/NEJMra052723 PubMed DOI

Mao X, Pan X, Peng X, Cheng T, Zhang X. Inhibition of titanium particle-induced inflammation by the proteasome inhibitor bortezomib in murine macrophage-like RAW 264.7 cells. Inflammation (2012) 35:1411–8.10.1007/s10753-012-9454-5 PubMed DOI

Weber C, Weber KS, Klier C, Gu S, Wank R, Horuk R, et al. Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T(H)1-like/CD45RO(+) T cells. Blood (2001) 97:1144–6. PubMed

Gilliland CT, Salanga CL, Kawamura T, Trejo J, Handel TM. The chemokine receptor CCR1 is constitutively active, which leads to G protein-independent, β-arrestin-mediated internalization. J Biol Chem (2013) 288:32194–210.10.1074/jbc.M113.503797 PubMed DOI PMC

Chanda D, Isayeva T, Kumar S, Hensel JA, Sawant A, Ramaswamy G, et al. Therapeutic potential of adult bone marrow-derived mesenchymal stem cells in prostate cancer bone metastasis. Clin Cancer Res (2009) 15:7175–85.10.1158/1078-0432.CCR-09-1938 PubMed DOI PMC

Dapunt U, Maurer S, Giese T, Gaida MM, Hänsch GM. The macrophage inflammatory proteins MIP1α (CCL3) and MIP2α (CXCL2) in implant-associated osteomyelitis: linking inflammation to bone degradation. Mediators Inflamm (2014) 2014:728619.10.1155/2014/728619 PubMed DOI PMC

Drynda A, Singh G, Buchhorn GH, Awiszus F, Ruetschi M, Feuerstein B, et al. Metallic wear debris may regulate CXCR4 expression in vitro and in vivo. J Biomed Mater Res A (2015) 103:1940–8.10.1002/jbm.a.35330 PubMed DOI

Kortesidis A, Zannettino A, Isenmann S, Shi S, Lapidot T, Gronthos S. Stromal-derived factor-l promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood (2005) 105:3793–801.10.1182/blood-2004-11-4349 PubMed DOI

Ha J, Choi HS, Lee Y, Kwon HJ, Song YW, Kim HH. CXC chemokine ligand 2 induced by receptor activator of NF-kappa B ligand enhances osteoclastogenesis. J Immunol (2010) 184:4717–24.10.4049/jimmunol.0902444 PubMed DOI

Krieger JR, Ogle ME, McFaline-Figueroa J, Segar CE, Temenoff JS, Botchwey EA. Spatially localized recruitment of anti-inflammatory monocytes by SDF-1α-releasing hydrogels enhances microvascular network remodelling. Biomaterials (2016) 77:280–90.10.1016/j.biomaterials.2015.10.045 PubMed DOI PMC

Awojoodu AO, Ogle ME, Sefcik LS, Bowers DT, Martin K, Brayman KL, et al. Sphingosine 1-phosphate receptor 3 regulates recruitment of anti-inflammatory monocytes to microvessels during implant arteriogenesis. Proc Natl Acad Sci U S A (2013) 110:13785–90.10.1073/pnas.1221309110 PubMed DOI PMC

Keeney M, Waters H, Barcay K, Jiang X, Yao Z, Pajarinen J, et al. Mutant MCP-1 protein delivery from layer-by-layer coatings on orthopedic implants to modulate inflammatory response. Biomaterials (2013) 34:10287–95.10.1016/j.biomaterials.2013.09.028 PubMed DOI PMC

Spiller KL, Nassiri S, Witherel CE, Anfang RR, Ng J, Nakazawa KR, et al. Sequential delivery of immunomodulatory cytokines to facilitate the M1-to-M2 transition of macrophages and enhance vascularization of bone scaffolds. Biomaterials (2015) 37:194–207.10.1016/j.biomaterials.2014.10.017 PubMed DOI PMC

Reeves AR, Spiller KL, Freytes DO, Vunjak-Novakovic G, Kaplan DL. Controlled release of cytokines using silk-biomaterials for macrophage polarization. Biomaterials (2015) 73:272–83.10.1016/j.biomaterials.2015.09.027 PubMed DOI PMC

Garash R, Bajpai A, Marcinkiewicz BM, Spiller KL. Drug delivery strategies to control macrophages for tissue repair and regeneration. Exp Biol Med (Maywood) (2016) 241:1054–63.10.1177/1535370216649444 PubMed DOI PMC

Graney PL, Roohani-Esfahani SI, Zreiqat H, Spiller KL. In vitro response of macrophages to ceramic scaffolds used for bone regeneration. J R Soc Interface (2016) 13:20160346.10.1098/rsif.2016.0346 PubMed DOI PMC

Ogle ME, Segar CE, Sridhar S, Botchwey EA. Monocytes and macrophages in tissue repair: implications for immunoregenerative biomaterial design. Exp Biol Med (Maywood) (2016) 241:1084–97.10.1177/1535370216650293 PubMed DOI PMC

Alvarez MM, Liu JC, Trujillo-de Santiago G, Cha BH, Vishwakarma A, Ghaemmaghami AM, et al. Delivery strategies to control inflammatory response: modulating M1-M2 polarization in tissue engineering applications. J Control Release (2016) 240:349–63.10.1016/j.jconrel.2016.01.026 PubMed DOI PMC

Goodman SB, Yao Z, Keeney M, Yang F. The future of biologic coatings for orthopaedic implants. Biomaterials (2013) 34:3174–83.10.1016/j.biomaterials.2013.01.074 PubMed DOI PMC

Slee JB, Christian AJ, Levy RJ, Stachelek SJ. Addressing the inflammatory response to clinically relevant polymers by manipulating the host response using ITIM domain-containing receptors. Polymers (Basel) (2014) 6:2526–51.10.3390/polym6102526 PubMed DOI PMC

Reyes CD, Petrie TA, Burns KL, Schwartz Z, García AJ. Biomolecular surface coating to enhance orthopaedic tissue healing and integration. Biomaterials (2007) 28:3228–35.10.1016/j.biomaterials.2007.04.003 PubMed DOI PMC

Raphel J, Karlsson J, Galli S, Wennerberg A, Lindsay C, Haugh MG, et al. Engineered protein coatings to improve the osseointegration of dental and orthopaedic implants. Biomaterials (2016) 83:269–82.10.1016/j.biomaterials.2015.12.030 PubMed DOI PMC

Ghanaati S, Unger RE, Webber MJ, Barbeck M, Orth C, Kirkpatrick JA, et al. Scaffold vascularization in vivo driven by primary human osteoblasts in concert with host inflammatory cells. Biomaterials (2011) 32:8150–60.10.1016/j.biomaterials.2011.07.041 PubMed DOI

Schlundt C, Khassawna TE, Serra A, Dienelt A, Wendler S, Schell H, et al. Macrophages in bone fracture healing: their essential role in endochondral ossification. Bone (2015).10.1016/j.bone.2015.10.019 PubMed DOI

Raggatt LJ, Wullschleger ME, Alexander KA, Wu AC, Millard SM, Kaur S, et al. Fracture healing via periosteal callus formation requires macrophages for both initiation and progression of early endochondral ossification. Am J Pathol (2014) 184:3192–204.10.1016/j.ajpath.2014.08.017 PubMed DOI

Kim YH, Furuya H, Tabata Y. Enhancement of bone regeneration by dual release of a macrophage recruitment agent and platelet-rich plasma from gelatin hydrogels. Biomaterials (2014) 35:214–24.10.1016/j.biomaterials.2013.09.103 PubMed DOI

Boelens JJ, van der Poll T, Dankert J, Zaat SA. Interferon-gamma protects against biomaterial-associated Staphylococcus epidermidis infection in mice. J Infect Dis (2000) 181:1167–71.10.1086/315344 PubMed DOI

Boelens JJ, van der Poll T, Zaat SA, Murk JL, Weening JJ, Dankert J. Interleukin-1 receptor type I gene-deficient mice are less susceptible to Staphylococcus epidermidis biomaterial-associated infection than are wild-type mice. Infect Immun (2000) 68:6924–31.10.1128/IAI.68.12.6924-6931.2000 PubMed DOI PMC

Li B, Jiang B, Dietz MJ, Smith ES, Clovis NB, Rao KM. Evaluation of local MCP-1 and IL-12 nanocoatings for infection prevention in open fractures. J Orthop Res (2010) 28:48–54.10.1002/jor.20939 PubMed DOI PMC

Omar O, Lennerås M, Svensson S, Suska F, Emanuelsson L, Hall J, et al. Integrin and chemokine receptor gene expression in implant-adherent cells during early osseointegration. J Mater Sci Mater Med (2010) 21:969–80.10.1007/s10856-009-3915-x PubMed DOI

Griffith M, Islam MM, Edin J, Papapavlou G, Buznyk O, Patra HK. The quest for anti-inflammatory and anti-infective biomaterials in clinical translation. Front Bioeng Biotechnol (2016) 4:71.10.3389/fbioe.2016.00071 PubMed DOI PMC

Karazisis D, Ballo AM, Petronis S, Agheli H, Emanuelsson L, Thomsen P, et al. The role of well-defined nanotopography of titanium implants on osseointegration: cellular and molecular events in vivo. Int J Nanomedicine (2016) 11:1367–82.10.2147/IJN.S101294 PubMed DOI PMC

Yumoto H, Hirota K, Hirao K, Miyazaki T, Yamamoto N, Miyamoto K, et al. Anti-inflammatory and protective effects of 2-methacryloyloxyethyl phosphorylcholine polymer on oral epithelial cells. J Biomed Mater Res A (2015) 103:555–63.10.1002/jbm.a.35201 PubMed DOI

Diagnosis and management of implant debris-associated inflammation

Periprosthetic Osteolysis: Mechanisms, Prevention and Treatment